Bacil Pharma Limited has proposed the appointment of Mr. Vivek Mukesh Yadav and Mr. Omprakash Pyarelal Sonar as Non-executive Independent Directors to strengthen its board's expertise in finance and market growth. The appointments, subject to shareholder approval at the next General Meeting, aim to enhance the company's financial strategy and operational presence. The intimation was submitted to BSE Limited on June 30, 2026, in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Mr. Vivek Mukesh Yadav (DIN: 11033957) brings significant experience in finance, accounts, and corporate management. His background includes reporting, financial planning, and compliance with regulatory frameworks, which the company expects will contribute to its financial and operational strategy. Mr. Yadav is not related to any of the existing directors of the company.

Mr. Omprakash Pyarelal Sonar (DIN: 11031877) is a professional in the trading industry with over seven years of experience. His expertise lies in product sales, brand establishment, and online sales strategies, which have been instrumental in driving market growth. Similar to Mr. Yadav, he is not related to any of the company's current directors.

The board will consider these resolutions in its upcoming meeting. The appointments are designated as Additional Non-executive Independent Director roles until ratified by the shareholders. The filing was signed by Ms. Chaitali Kalpataru Shah, Director & CFO of Bacil Pharma Limited.

Proposed Appointments

Bacil Pharma has withdrawn its intimation regarding the appointment of Mr. Aayush Shah and Mr. Ankitkumar Surendrakumar Agrawal as Non-Executive Independent Directors. The company stated it did not receive the necessary consent and other required documents from the proposed directors. Consequently, the Board has not approved the proposed appointments, which were initially intended to strengthen corporate governance and comply with Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

The earlier proposal, filed on June 29, 2026, had detailed the extensive experience of the candidates. Mr. Aayush Shah brought nine years of experience as a Company Secretary and Compliance Officer, with expertise in Corporate Laws, Security Laws, and Capital Market. Mr. Ankitkumar Surendrakumar Agrawal, a qualified Company Secretary with over seven years of experience, was serving as the Company Secretary for Prozeal Green Energy Limited since November 2023. Both individuals were unrelated to the existing directors.

Director Profiles

The withdrawal was intimated by Mrs. Chaitali Kalpataru Shah, Director & CFO of Bacil Pharma Limited. The company has requested the stock exchange to take the information on record.